Vijay Kumar

Vijay Kumar, PhD, serves as an Assistant Professor in the Department of Surgery at Morehouse School of Medicine, where he directs the Laboratory of Tumor Immunology and Immunotherapy. His research focuses on tumor immunology and immunotherapy with emphasis on innate immune mechanisms and the tumor microenvironment.

His academic background includes:

• PhD in Immunology and Medical Microbiology from Panjab University
• MSc in Toxicology from Hamdard University
• BSc in Botany, Zoology, and Chemistry from DAV College

Dr. Kumar's research centers on understanding immune dysregulation in cancer, particularly through Toll-like receptors and macrophage biology. His work explores how inflammation and immune homeostasis influence tumor progression, aiming to develop novel immunotherapeutic strategies. Recent editorial contributions demonstrate expertise in translating fundamental immunological concepts into clinical applications, with significant focus on methodological advances in immune protocols.

His publication record (2017-2024) reveals consistent scholarly output in immunological mechanisms, showing evolution from foundational topics like sepsis and vaccines toward contemporary cancer immunology. Key trends include historical perspectives on immunological discoveries (e.g., 140 years of macrophage research, 30 years of Toll-like receptor studies) and methodological frameworks for immune homeostasis in tumor contexts.

No scientific awards were mentioned in the provided documentation.

Information regarding student advising, grant funding, or specific mentorship activities was not provided in the available text, though his faculty position implies involvement in academic supervision within the Department of Surgery.

Dr. Kumar leads the Laboratory of Tumor Immunology and Immunotherapy, which investigates immune cell interactions within the tumor microenvironment. The lab's work integrates historical immunological perspectives with modern therapeutic approaches, focusing on restoring immune homeostasis as a strategy for cancer treatment.